---
title: "BDTX.US (BDTX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BDTX.US/news.md"
symbol: "BDTX.US"
name: "BDTX.US"
parent: "https://longbridge.com/en/quote/BDTX.US.md"
datetime: "2026-05-21T09:33:30.682Z"
locales:
  - [en](https://longbridge.com/en/quote/BDTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BDTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BDTX.US/news.md)
---

# BDTX.US (BDTX.US) — Related News

### [MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch](https://longbridge.com/en/news/287035625.md)
*2026-05-20T09:04:22.000Z*
> In Tuesday's trading, biotech stocks saw significant gains. MetaVia Inc. (MTVA) surged over 69% as it advances its obesi

### [Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028](https://longbridge.com/en/news/285630631.md)
*2026-05-07T22:25:19.000Z*
> TD Cowen analyst Marc Frahm has reiterated a Buy rating on Black Diamond Therapeutics (BDTX) stock, citing its different

### [Black Diamond Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285539533.md)
*2026-05-07T11:22:11.000Z*
### [Black Diamond Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285538773.md)
*2026-05-07T11:19:19.000Z*
### [Black Diamond Group declares CAD 0.045 dividend](https://longbridge.com/en/news/284866433.md)
*2026-05-01T05:01:18.000Z*
> Black Diamond Group (BDIMF) has declared a quarterly dividend of CAD 0.045 per share, consistent with previous dividends

### [Black Diamond Therapeutics | 10-K: FY2025 Revenue: USD 70 M](https://longbridge.com/en/news/283975648.md)
*2026-04-24T09:55:57.000Z*
### [Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting | BDTX Stock News](https://longbridge.com/en/news/283521398.md)
*2026-04-21T06:40:36.000Z*
> Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at

### [Black Diamond Sets Date for Q1 2026 Results and Investor Call](https://longbridge.com/en/news/282253606.md)
*2026-04-09T21:49:53.000Z*
> Black Diamond Sets Date for Q1 2026 Results and Investor Call